GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tempest Therapeutics Inc (NAS:TPST) » Definitions » Net Change in Cash

Tempest Therapeutics (Tempest Therapeutics) Net Change in Cash : $9.48 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Tempest Therapeutics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Tempest Therapeutics's Net Change in Cash for the three months ended in Mar. 2024 was $-6.90 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was $9.48 Mil.

Tempest Therapeutics Net Change in Cash Historical Data

The historical data trend for Tempest Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tempest Therapeutics Net Change in Cash Chart

Tempest Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Net Change in Cash
15.58 33.01 -20.23 8.08

Tempest Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.31 -5.32 -6.47 28.17 -6.90

Tempest Therapeutics Net Change in Cash Calculation

Tempest Therapeutics's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-27.357+-0.17+35.602+0
=8.08

Tempest Therapeutics's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-7.186+-0.168+0.45+0
=-6.90

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tempest Therapeutics Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Tempest Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Tempest Therapeutics (Tempest Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tempest Therapeutics Inc (NAS:TPST) » Definitions » Net Change in Cash
Comparable Companies
KRON SYRS LGVN RANI CLNN CRVO TIL CTCX CLSD SLDB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
3OS:Germany 3OS:Germany
Address
2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005
Website
https://www.tempesttx.com
Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.
Executives
Justin Trojanowski officer: Corporate Controller C/O TEMPEST THERAPEUTICS, INC., 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 94080
Nicholas Maestas officer: VP of Strategy and Finance 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 20005
Versant Venture Capital Vi, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Side Fund Iv, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Venture Capital Iv, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures Iv, Llc 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Thomas Woiwode director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures Vi Gp-gp, Llc 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures Vi Gp, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Vantage Ii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp-gp, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Thomas W. Dubensky director, officer: President C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Samuel Whiting officer: Chief Medical Officer C/O TEMPEST THERAPEUTICS, INC., 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 94080
Rock Springs Capital Llc 10 percent owner 650 SOUTH EXETER STREET, SUITE 1070, BALTIMORE MD 21202

Tempest Therapeutics (Tempest Therapeutics) Headlines

From GuruFocus

Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

By Marketwired • 10-11-2023

Tempest to Present at the H.C. Wainwright 25th Annual Global Investment Conference

By Marketwired • 09-05-2023

Tempest Announces Data Presentations, including a Late-Breaking Presentation on TPST-1120, at the SITC Annual Meeting

By Value_Insider Value_Insider • 11-02-2022

Tempest Adopts Limited Duration Stockholder Rights Plan

By Marketwired • 10-11-2023

Tempest to Present at the Jefferies Global Healthcare Conference

By sperokesalga sperokesalga • 05-31-2023

Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting

By sperokesalga sperokesalga • 04-26-2023

Tempest to Participate in Panel Discussion at 2022 William Blair Biotech Focus Conference

By GuruFocusNews GuruFocusNews • 07-07-2022

Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together

By Marketwired • 07-19-2023

Tempest Presents Data Showing TPST-1120-Induced Pharmacodynamic Changes Consistent with Clinical Benefit Observed in Patients with Cancer

By Value_Insider Value_Insider • 11-10-2022

Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors at 2022 ASCO Annual Meeting

By PurpleRose PurpleRose • 07-15-2022